Daymark Wealth Partners LLC Sells 11,070 Shares of GSK plc (NYSE:GSK)

Daymark Wealth Partners LLC trimmed its holdings in shares of GSK plc (NYSE:GSK) by 49.6% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 11,270 shares of the pharmaceutical company’s stock after selling 11,070 shares during the quarter. Daymark Wealth Partners LLC’s holdings in GSK were worth $381,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Eastern Bank acquired a new position in shares of GSK during the 3rd quarter worth approximately $26,000. ST Germain D J Co. Inc. grew its position in GSK by 195.5% during the fourth quarter. ST Germain D J Co. Inc. now owns 789 shares of the pharmaceutical company’s stock worth $27,000 after buying an additional 522 shares in the last quarter. Sunbelt Securities Inc. increased its stake in GSK by 73.8% during the 3rd quarter. Sunbelt Securities Inc. now owns 711 shares of the pharmaceutical company’s stock worth $29,000 after acquiring an additional 302 shares during the period. Concord Wealth Partners raised its holdings in GSK by 231.8% in the 3rd quarter. Concord Wealth Partners now owns 783 shares of the pharmaceutical company’s stock valued at $32,000 after acquiring an additional 547 shares in the last quarter. Finally, Fortitude Family Office LLC bought a new stake in shares of GSK during the 3rd quarter valued at $42,000. Institutional investors and hedge funds own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of research firms recently commented on GSK. Guggenheim downgraded GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Jefferies Financial Group lowered shares of GSK from a “buy” rating to a “hold” rating and reduced their price target for the stock from $53.00 to $39.50 in a research report on Tuesday, November 12th. Finally, StockNews.com downgraded shares of GSK from a “strong-buy” rating to a “buy” rating in a research report on Tuesday. Six investment analysts have rated the stock with a hold rating, one has given a buy rating and three have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $43.25.

GSK Price Performance

GSK stock opened at $34.08 on Friday. The stock has a market cap of $70.63 billion, a price-to-earnings ratio of 22.13, a P/E/G ratio of 1.32 and a beta of 0.63. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53. The company has a 50 day simple moving average of $33.89 and a 200 day simple moving average of $37.87. GSK plc has a 1 year low of $31.72 and a 1 year high of $45.92.

GSK Increases Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, January 9th. Stockholders of record on Friday, November 15th were issued a dividend of $0.3928 per share. The ex-dividend date was Friday, November 15th. This is an increase from GSK’s previous quarterly dividend of $0.38. This represents a $1.57 annualized dividend and a dividend yield of 4.61%. GSK’s dividend payout ratio is 96.10%.

About GSK

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.